President & CSO
- PI, Biogen: Inflammation, autoimmunity, fibrosis, oncology
- Since 2012 focused on new company development
- Author on more than 30 patents and approx. 100 publications & recent IO reviews
Paul is a noted research scientist and biotechnology executive with extensive strategic and leadership experience. His industry expertise spans bench to IND to clinical trials for biologics, small molecules and cellular therapeutics. His recent accomplishments include the launch of successful new biotech companies. In 2012 he engaged with MPM Capital to launch CoStim Pharmaceuticals, one of the first private immuno-oncology companies (bought by Novartis), In 2013 he partnered with X-Chem Inc to create X-Rx Discovery, a privately held drug discovery company focused on oncology, inflammation, and fibrosis that successfully out-licensed programs in oncology and fibrosis.
Paul’s ability to work so broadly across the industry grew from his outstanding early career at Repligen and Biogen, highlighted by multiple successful drug-development campaigns, over 40 patents filed and granted, and approximately 100 peer-reviewed publications including publications in Nature Reviews Drug Discovery, Annual Reviews, Immunity, Journal of Experimental Medicine, Journal of Clinical Investigation, and PNAS USA. In 2015 he co-authored and edited the book “Novel Therapeutic Approaches to the Treatment of Cancer”, for Springer Nature. Paul continues to lecture and write extensively. His seminal observations on drug development, immunology, immuno-oncology and cell therapy are can be found at sugarconebiotech.com Blog, on slideshare.net/PaulDRennert and via his highly influential Twitter commentary @PDRennert.